Please use this identifier to cite or link to this item: http://hdl.handle.net/1942/39106
Full metadata record
DC FieldValueLanguage
dc.contributor.authorVansteenkiste, J. F.-
dc.contributor.authorDemedts, I.-
dc.contributor.authorPons-Tostivint, E.-
dc.contributor.authorBiesma, B.-
dc.contributor.authorBorm, F.-
dc.contributor.authorColinet, B.-
dc.contributor.authorCUPPENS, Kristof-
dc.contributor.authorDerijcke, S.-
dc.contributor.authorGreillier, L.-
dc.contributor.authorJuergens, J.-
dc.contributor.authorMoro-Sibilot, D.-
dc.contributor.authorPerol, M.-
dc.contributor.authorSebastian, M.-
dc.contributor.authorSkrzypski, M.-
dc.contributor.authorTheelen, W.-
dc.contributor.authorVan De Kerkhove, C.-
dc.contributor.authorCollodoro, M.-
dc.contributor.authorPlumas, J.-
dc.contributor.authorDebruyne, C.-
dc.contributor.authorSibille, A.-
dc.date.accessioned2023-01-03T09:26:08Z-
dc.date.available2023-01-03T09:26:08Z-
dc.date.issued2022-
dc.date.submitted2022-12-23T13:56:25Z-
dc.identifier.citationANNALS OF ONCOLOGY, 33 (7) , p. S1086 (Art N° 1176P)-
dc.identifier.urihttp://hdl.handle.net/1942/39106-
dc.description.sponsorshipPDC*line Pharma SAS-
dc.language.isoen-
dc.publisherELSEVIER-
dc.titleOpen-label, dose escalation, phase I/II study to assess safety, tolerability, immunogenicity and preliminary clinical activity of the therapeutic cancer vaccine PDC*lung01 with or without anti-programmed death-1 (PD-1) treatment in patients with non-small cell lung cancer (NSCLC)-
dc.typeJournal Contribution-
local.bibliographicCitation.conferencedateSEP 09-13, 2022-
local.bibliographicCitation.conferencenameAnnual Meeting of the European-Society-for-Medical-Oncology (ESMO)-
local.bibliographicCitation.conferenceplaceELECTR NETWORK-
dc.identifier.issue7-
dc.identifier.spageS1086-
dc.identifier.volume33-
local.format.pages1-
local.bibliographicCitation.jcatM-
local.publisher.placeRADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS-
local.type.refereedRefereed-
local.type.specifiedMeeting Abstract-
local.bibliographicCitation.artnr1176P-
dc.identifier.doi10.1016/j.annonc.2022.07.1299-
dc.identifier.isi000866211601438-
local.provider.typewosris-
local.description.affiliation[Vansteenkiste, J. F.] Univ Hosp Leuven, Resp Oncol Unit Pulmonol, Campus Gasthuisberg, Leuven, Belgium.-
local.description.affiliation[Demedts, I.] AZ Delta, Dept Pulm Dis, Campus Rumbeke, Roeselare, Belgium.-
local.description.affiliation[Pons-Tostivint, E.] CHU Nantes, Med Oncol Dept, Hotel Dieu, Nantes, France.-
local.description.affiliation[Biesma, B.] Jeroen Bosch Hosp, Dept Pulm Dis, Shertogenbosch, Netherlands.-
local.description.affiliation[Borm, F.] LUMC Univ Med Centrum, Dept Pulmonol, Leiden, Netherlands.-
local.description.affiliation[Colinet, B.] GHdC Grand Hop Charleroi, Pulmonol & Oncol Unit, Charleroi, Belgium.-
local.description.affiliation[Cuppens, K.] Virga Jesse Ziekenhuis, Pulmonol Dept, Hasselt, Belgium.-
local.description.affiliation[Derijcke, S.] AZ Groeninge, Pulmonol Thorac Oncol, Campus Kennedylaan, Kortrijk, Belgium.-
local.description.affiliation[Greillier, L.] Hop St Marguerite Assistance Publ Hop Marseille, Multidisciplinary Oncol & Therapeut Innovat, Marseille, France.-
local.description.affiliation[Juergens, J.] Kliniken Stadt Koln gGmbH, Dept Pulm Dis, Cologne, Germany.-
local.description.affiliation[Moro-Sibilot, D.] CHU Grenoble Alpes, Thorac Oncol Dept, La Tronche Hop, Site Nord, La Tronche, France.-
local.description.affiliation[Perol, M.] Ctr Leon Berard, Dept Med Oncol, Lyon, France.-
local.description.affiliation[Sebastian, M.] Johannes Wolfgang Goethe Univ, Univ Klinikum Frankfurt, Dept Hematol Med Oncol, Frankfurt, Germany.-
local.description.affiliation[Skrzypski, M.] Med Univ Gdansk, Katedra Klin Onkol Radioterapii, Gdansk, Poland.-
local.description.affiliation[Theelen, W.] Netherlands Canc Inst, Thorac Oncol Dept, Amsterdam, Netherlands.-
local.description.affiliation[Van De Kerkhove, C.] Vitaz, Dept Pulm Dis, St Niklaas, Belgium.-
local.description.affiliation[Collodoro, M.] PDC Line Pharma SA, QA QC, Liege, Belgium.-
local.description.affiliation[Plumas, J.] PDC Line Pharma SAS, Dept Res & Dev, Grenoble Res Lab, La Tronche, France.-
local.description.affiliationPDC Line Pharma SA, Clin Dept, Liege, Belgium.-
local.description.affiliation[Sibille, A.] Ctr Hosp Univ Sart Tilman, Pulmonol Dept, Liege, Belgium.-
local.uhasselt.internationalyes-
item.fullcitationVansteenkiste, J. F.; Demedts, I.; Pons-Tostivint, E.; Biesma, B.; Borm, F.; Colinet, B.; CUPPENS, Kristof; Derijcke, S.; Greillier, L.; Juergens, J.; Moro-Sibilot, D.; Perol, M.; Sebastian, M.; Skrzypski, M.; Theelen, W.; Van De Kerkhove, C.; Collodoro, M.; Plumas, J.; Debruyne, C. & Sibille, A. (2022) Open-label, dose escalation, phase I/II study to assess safety, tolerability, immunogenicity and preliminary clinical activity of the therapeutic cancer vaccine PDC*lung01 with or without anti-programmed death-1 (PD-1) treatment in patients with non-small cell lung cancer (NSCLC). In: ANNALS OF ONCOLOGY, 33 (7) , p. S1086 (Art N° 1176P).-
item.accessRightsRestricted Access-
item.fulltextWith Fulltext-
item.contributorVansteenkiste, J. F.-
item.contributorDemedts, I.-
item.contributorPons-Tostivint, E.-
item.contributorBiesma, B.-
item.contributorBorm, F.-
item.contributorColinet, B.-
item.contributorCUPPENS, Kristof-
item.contributorDerijcke, S.-
item.contributorGreillier, L.-
item.contributorJuergens, J.-
item.contributorMoro-Sibilot, D.-
item.contributorPerol, M.-
item.contributorSebastian, M.-
item.contributorSkrzypski, M.-
item.contributorTheelen, W.-
item.contributorVan De Kerkhove, C.-
item.contributorCollodoro, M.-
item.contributorPlumas, J.-
item.contributorDebruyne, C.-
item.contributorSibille, A.-
crisitem.journal.issn0923-7534-
crisitem.journal.eissn1569-8041-
Appears in Collections:Research publications
Files in This Item:
File Description SizeFormat 
1176PO~1.PDF
  Restricted Access		Published version85.34 kBAdobe PDFView/Open    Request a copy
Show simple item record

WEB OF SCIENCETM
Citations

1
checked on Oct 5, 2024

Google ScholarTM

Check

Altmetric


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.